α-Gal-Based Vaccines: Advances, Opportunities, and Perspectives

Adnan Hodžić, Lourdes Mateos Hernandez, José de La Fuente, Alejandro Cabezas Cruz

HAL Id: hal-02951804
https://hal.inrae.fr/hal-02951804

Submitted on 21 Nov 2022

1   **α-Gal-based vaccines: Advances, opportunities, and perspectives**

2   Adnan Hodžić,[1,*] Lourdes Mateos-Hernández,[2] José de la Fuente,[3,4] Alejandro Cabezas-

3   Cruz[2,*]

4   [1]Institute of Parasitology, Department of Pathobiology, University of Veterinary Medicine Vienna,

5   Veterinaerplatz 1, 1210 Vienna, Austria

6   [2]UMR BIPAR, INRAE, ANSES, Ecole Nationale Vétérinaire d'Alfort, Université Paris-Est, 14 rue Pierre et

7   Marie Curie, 94706 Maisons-Alfort, France

8   [3]SaBio, Instituto de Investigación de Recursos Cinegéticos, IREC-CSIC-UCLM-JCCM, Ronda de Toledo s/n,

9   13005 Ciudad Real, Spain

10   [4]Department of Veterinary Pathobiology, Center for Veterinary Health Sciences, Oklahoma State University,

11   Stillwater, OK 74078, USA

12   ***Correspondence:** adnan.hodzic@vetmeduni.ac.at (A. Hodžić) and cabezasalejandrocruz@gmail.com (A.

13   Cabezas-Cruz)

14

16   **ABSTRACT**

17   Humans and crown catarrhines evolved with the inability to synthesize the oligosaccharide

18   galactose-α-1,3-galactose (α-Gal). In turn, they naturally produce high quantities of the

19   glycan-specific antibodies, which can be protective against infectious agents exhibiting the

20   same carbohydrate modification on their surface coat. The protective immunity induced by α-

21   Gal is ensured through an antibody-mediated adaptive and cell-mediated innate immune

22   response. Therefore, the α-Gal antigen represents an attractive and feasible target for

23   developing glycan-based vaccines against multiple diseases. In this review article, we provide

24   an insight into our current understanding of the mechanisms involved in the protective

25   immunity to α-Gal and discuss the possibilities and challenges in developing a single-antigen

26   pan-vaccine for prevention and control of parasitic diseases of medical and veterinary

27   concern.

The rationale for developing an α-Gal-based vaccine against parasites

Carbohydrates are abundantly expressed on the surface of nearly all cells in both prokaryotic and eukaryotic organisms, where they exist in the form of complex glycans, polysaccharides, and oligosaccharides linked to proteins and lipids [1,2]. Indeed, many pathogens causing diseases in humans and animals contain unique carbohydrate structures on their surface coat that serve as receptors by which the pathogenic organisms attach to and invade host cells [3-11]. The pathogen carbohydrate molecules are often structurally different from those displayed on mammalian host cells and are thereby recognized by the host immune system [2]. Natural infections and exposure to the carbohydrate antigens on infectious agents can elicit an innate immune response and activate B cells to produce protective glycan-binding antibodies (Abs) in the host. The potential of the surface **glycotopes** (see **Glossary**) to induce such a potent immune response makes carbohydrates attractive and feasible targets for vaccine development [1,2,12]. Accordingly, the scientific interest in exploiting the immunogenic glycan antigens as vaccine constituents has considerably increased in the last years and it resulted in the development of efficient glycoconjugate vaccines targeting encapsulated bacteria strains such as *Haemophilus influenzae* type B, *Streptococcus pneumonia*, and *Neisseria meningitidis* [1]. Significant progress has also been made with conjugate vaccine formulations for control of other viral, parasitic, and fungal diseases [2,13,14].

The oligosaccharide galactose-α-1,3-galactose (α-Gal) is currently one of the most interesting carbohydrates that attracts growing attention from the scientific community after it was recognized as a major allergen responsible for the production of specific immunoglobulin (Ig)E that mediates delayed and severe anaphylactic reaction to mammalian meat consumption in humans previously exposed to tick bites [15-20]. This novel type of tick-

53　induced food allergy is better known as red meat allergy or the α-Gal syndrome [21-23]. The

54　terminal α-Gal residues have recently been found in the saliva of several tick species, but the

55　mechanism by which ticks promote an anti-α-Gal response and high-level sensitization in

56　humans is not known [24-28]. It has been, however, hypothesized that tick salivary

57　prostaglandin E2 (PGE2) may induce class switch recombination on B cells leading to IgE

58　production [29]. Another possible explanation is that α-Gal from tick salivary

59　glycoconjugates is presented to **antigen-presenting cells (APCs)** and B lymphocytes in the

60　context of T helper (Th) 2 cell-mediated immunity, which leads to the differentiation of α-

61　Gal-specific B cells into IgE secreting plasma cells [29]. The way how α-Gal is captured,

62　processed and presented to CD4+ T cells seems to determine whether the antigen is

63　recognized by the host immune system as harmless, like possibly in case of helminths and

64　fungi, or hazardous [9,23]. By contrast to the detrimental effect of the IgE immune responses

65　to α-Gal, the production of IgG and IgM isotypes induced by gut microbiota seems to be

66　beneficial as these Abs can be protective against different pathogens exhibiting carbohydrates

67　with the similar α-Gal modification on their surface [4-6,8,10,11,30]. In this review, we

68　provide a summary of the recent advances in our understanding of the mechanisms involved

69　in the protective immunity to α-Gal and discuss the possibilities in developing an α-Gal-

70　based vaccine for prevention and control of multiple parasitic diseases of medical and

71　veterinary importance.

72

73　**The α-Gal epitope and anti-α-Gal antibodies**

74　The α-Gal epitope is a unique oligosaccharide naturally produced on glycoproteins and

75　glycolipids of non-primate mammals, prosimians, and New World monkeys [31]. The

76　glycosylation enzyme α-1,3-galactosyltransferase (α1,3GT), encoded by the *ggta1* gene in

77　mammals, catalyzes the synthesis of the epitope by transferring galactose molecule from

78   uridine diphosphate (UDP)-Gal to N-acetyllactosaminide [32]. Conversely, humans and Old

79   World primates lack the synthetic machinery to produce the α-Gal due to the functional

80   inactivation of the *ggta1* gene, caused by several deletions in the DNA sequence that encodes

81   premature stop codons [33-35]. Non-mammalian vertebrates (e.g. birds, fish) do not have the

82   *ggta1* gene and also lack the α-Gal [10,11,36]. In humans, the α-Gal epitope is expressed

83   only in the blood group B glycoconjugates (Galα1-3[Fucα1-2]Galβ1-4Glc-ceramide) [37].

84   Therefore, humans and other vertebrates with this *ggta1* gene modification lost immune

85   tolerance to non-cryptic α-Gal moieties and are consequently able to produce large quantities

86   of Abs that specifically bind to the non-self-antigen [38,39]. However, due to the structural

87   similarity between antigen B and α-Gal, individuals with blood groups AB and B produce

88   lower Ab levels against the related antigens α-Gal (Galα1-3Galβ1-4GlcNAc) and gal2 (Galα-

89   1,3-Gal) [40]. The disruption of the *ggta1* gene in our primate ancestors, estimated to have

90   occurred almost 28 million years ago, was likely exerted by a strong selective pressure of an

91   infectious agent and the subsequent acquisition of immune-resistance to pathogens expressing

92   α-Gal [31,39]. This evolutionary scenario can be further supported by the following facts: (*i*)

93   enveloped viruses express α-Gal when propagated in cells with active *ggta1* gene; (*ii*)

94   helminths, protozoa, bacteria, and fungi also express carbohydrates with terminal α-Gal

95   moieties; and (*iii*) anti-α-Gal Abs can neutralize pathogenic organisms exhibiting α-Gal

96   epitopes [37].

97

98   Anti-α-Gal Abs, in particular IgG, IgM, and IgA isotypes are naturally generated in healthy

99   human individuals as an immunological response to continuous antigenic stimulation by

100 Gram-negative bacteria of gut flora, which express very diverse terminal and non-reducing α-

101 Gal-linked glycans, predominately in Galα1,2-, Galα1,4-, and Galα1,6-R forms [41,42]. A

102 high   proportion   of   individuals   (>70%)   in   healthy   populations   exhibit   α-1,3-

103 galactosyltransferase sequences in the bacteria of their gut microbiome [43]. Notably, α-1,3-

104 galactosyltransferase genes in bacteria and mammals were not evolutionarily related.

105 However, other immune-mediated mechanisms may also be activated in response to α-Gal

106 [44]. For instance, high levels of anti-α-Gal Abs have also been reported in human patients

107 infected with *Trypanosoma* spp. (Kinetoplastida), *Leishmania* spp. (Kinetoplastida), and

108 *Plasmodium* spp. (Apicomplexa), indicating the polyreactive nature of the Abs [4,45-48].

109 However, pathogen-specific anti-α-Gal seems to have different specificities than Abs

110 produced towards the α-Gal from enterobacteria [3-5,45,49]. Nevertheless, IgG2 and IgM

111 Abs induced by α-Gal expressed on pig cells are a major immunological barrier preventing

112 the transplantation of pig organs into humans [50].

113

114 **Mechanisms of the protective α-Gal immunity against parasites**

115 In general, the α-Gal epitope has significant clinical potential in the possibility of developing

116 an α-Gal glycovaccine or other interventions such as pro- and postbiotics to induce a

117 protective α-Gal immune response against multiple diseases (**Figure 1, Key Figure**)

118 [4,5,8,10,11,13,14,30]. The immunity induced by α-Gal influences pathogen infection and its

119 multiplication by various mechanisms including B cell maturation, antibody-mediated

120 **opsonization** of α-Gal-containing pathogens, activation of the **complement system**, Fc-

121 receptor (FcR)-mediated phagocytosis, activation of macrophage response, antibody-

122 mediated interference with the α-Gal antagonistic effect to promote **toll-like receptor 2**

123 **(TLR2)/nuclear factor kappa-light-chain-enhancer (NF-κB)**-mediated immune response

124 and upregulation of proinflammatory **cytokines** (**Table 1**).

125

126 *Plasmodium spp.*

Several epidemiological studies uncovered a strong correlation between α-Gal-specific IgM Abs and protection from *Plasmodium* infections in humans [47,48,51,52,53], but the first experimentally proved evidence for the protective role of α-Gal-induced immunity was provided by Yilmaz et al. [4]. In their seminal study, C57BL/6 *ggta1*-knockout (*ggta1*-KO) mice, which like humans do not express α-Gal on their cells, were used as an animal model to assess the protective effect of anti-α-Gal Abs against *Plasmodium berghei* and *Plasmodium yoelii* infections. *Plasmodium* parasites express the α-Gal carbohydrate possibly bound to glycosylphosphatidylinositol (GPI)-anchored surface proteins [4,54]. The results of the experimental study showed that gut colonization by *Escherichia coli* O86:B7 that expresses high levels of α-Gal inhibits the parasite transmission by *Anopheles* mosquitoes. In particular, anti-α-Gal IgM Abs produced in response to *E. coli* O86:B7 blocked infection with *Plasmodium* spp. in 60% of the mice, but this was not the case when the mice were or were not exposed to *E. coli* K12, a serotype which does not produce α-Gal. Immunization of *ggta1*-KO mice with rabbit red blood cell membranes (rRBCM) or synthetic α-Gal linked to bovine serum albumin (α-Gal-BSA) elicited the production of serum IgM and IgG (IgG1, IgG2b, and IgG3 subclasses) Abs, but the levels of circulating IgA and IgE Abs were not detectable. A significant increase in anti-α-Gal Ab production was also observed when mice were immunized with rRBCM supplemented with TLR9 agonist adjuvant and this was associated with an 88% reduction in the relative risk of *Plasmodium* infection compared to 61% risk reduction without adjuvant in combination. Further experiments revealed that the protective effect of α-Gal immunization is mediated via B cell-dependent mechanisms, as well as that both IgM and IgG Ab classes confer protection against malaria transmission, thereby providing **sterile immunity**. The cytotoxic effect of Abs produced towards α-Gal appears to be mediated by the classical complement activation. Furthermore, the protective activity of anti-α-Gal Abs was not observed when *Plasmodium* sporozoites were introduced

152   intravenously, suggesting that the protection induced by α-Gal immunization is only exerted

153   in the dermis, where the pathogen is inoculated by mosquitoes. Once the parasite reaches the

154   blood, the protective effect of the α-Gal immunity is no longer productive, and the

155   parasitaemia, disease severity, as well as mortality rate were similar among infected *ggta1-*

156   KO mice regardless of the source of the α-Gal residues, i.e. oral administration of *E. coli*

157   O86:B7 or α-Gal immunization. Based on these findings, it has been proposed that α-Gal-

158   induced immunity protects against *Plasmodium* transmission, but not against the blood stages

159   of this parasite. These results suggest that anti-α-Gal immunity can influence malaria

160   incidence, but not disease severity or protection once the disease is established. In agreement

161   with the hypothesis, individuals from Mali and Senegal exposed to mosquito bites were not

162   infected by *Plasmodium falciparum* when having high anti-α-Gal Ab levels [4,48]. In

163   addition, the frequency of blood type B in African countries was positively correlated with

164   the incidence of malaria, possibly due to weak anti-α-Gal immunity in populations with a

165   high frequency of blood type B [48]. By contrast, a negative correlation was observed

166   between the frequency of blood type A and the incidence of malaria [48]. A 4-year

167   prospective cohort study in childhood malaria in Mali showed that children having blood

168   types B and AB had higher incidence rate (blood type B: 1.63 and blood type AB: 1.65)

169   compared to those children with blood types A and O (blood type A: 1.57 and blood type O:

170   1.45). This supports the role of blood type B in reducing anti-α-Gal Abs, which in turn

171   increases the incidence of malaria [55].

172

173   ***Leishmania spp.***

174   *Leishmania* spp. is another group of important and widespread protozoan parasites containing

175   terminal α-Gal epitopes and thus they represent potential targets for vaccine development

176   against human visceral and cutaneous **leishmaniasis** [5,6,46]. Variable levels of the α-Gal

177 moieties have been so far observed in *Leishmania major*, *Leishmania infantum*, and

178 *Leishmania amazonensis* [5,6,56]. *Leishmania major*, and perhaps other *Leishmania* species,

179 synthesize Type-II glycoinositolphospholipids (GIPL)-2 and GIPL-3, which are capped with

180 terminal, non-reducing and highly immunogenic α-galactopyranosyl residues with different

181 structural configurations [5,57]. These glycolipids are expressed in abundance in the

182 amastigote stages, residing in macrophages of mammalian hosts [57]. In a recent study, three

183 different neoglycoproteins (NGPs) containing synthetic α-Gal in different configurations,

184 namely Galα(1,6)Galβ-BSA (NGP5B), Galα(1,4)Galβ-BSA (NGP12B), and Galα(1,3)Galα-

185 BSA (NGP17B), were evaluated as potential prophylactic vaccine candidates against *L.*

186 *major* [5]. The *ggta1*-KO mice immunized with the three NGPs tested produced high levels

187 of specific anti-α-Gal IgG Abs. However, only NGP5B administered alone or in combination

188 with CpG adjuvant displayed a significant complement-independent lytic activity against

189 infective metacyclic *L. major* promastigotes. Incubation of NGP5B and NGP5B + CpG

190 immunized mice sera with *L. major* promastigotes caused lysis of 44% and 60%

191 promastigotes, respectively. In contrast to *Plasmodium* parasites [4], the lytic effect was

192 documented only when the complement was heat inactivated. Furthermore, mice immunized

193 with NGP5B had significantly reduced parasite load and the size of footpad lesions by 96%

194 compared to control groups. Similarly, a significant reduction in *L. infantum* and *L.*

195 *amazonensis* parasite load in liver and spleen along with increased levels of anti-α-Gal IgG

196 were observed in another study in which *ggta1*-KO mice were immunized with Qβ virus-like

197 particle bearing α-Gal trisaccharide [6]. In NGP5B immunized mice, a strong protective Th1

198 cellular immune response with increased levels of proinflammatory cytokines such as

199 interleukin (IL)-12p40, IL-2, and interferon (IFN)-γ were recorded. NGP5B and NGP5B +

200 CpG in mice induced a robust CD4$^+$ and a CD8$^+$ T cell response, which is essential for the

201 protection against *L. major*. Taken together, immunization with this NGP5B alone or with

202 CpG in combination induce partial, but significant protective α-Gal immunity against the *L.*

203 *major* infection in mice.

204

205 ***Trypanosoma cruzi***

206 *Trypanosoma cruzi* has a complex carbohydrate-rich surface coat that contains GPI-anchored

207 mucins (tGPI-mucins) with the linear and immunodominant α-Gal glycotope and several as

208 yet uncharacterized branched terminal α-Gal *O*-glycans [3]. Previous studies showed that

209 patients with acute and chronic **Chagas disease** produce high levels of anti-α-Gal Abs that

210 specifically recognize the tGPI-mucins on trypomastigotes and are considerably different in

211 terms of specificity and biological activity than natural anti-α-Gal Abs produced in response

212 to gut microbiota [3,45,49]. The latter also exhibits substantially lower lytic activity against

213 *Trypanosoma* trypomastigotes [3,45]. Therefore, Portillo et al. [8] recently investigated the

214 efficacy of the *T. cruzi* immunodominant α-Gal epitope as a prophylactic glycovaccine

215 candidate in the acute model of Chagas disease. They immunized *ggta1*-KO mice by

216 intraperitoneal injection of synthetic α-Gal linked to human serum albumin (Galα3LN-HSA

217 or Galα1-3Galβ1-4GlcNAc-HSA), which is almost structurally identical to that found on

218 tGPI-mucins. This comprehensive study clearly demonstrated that mice immunized with

219 Galα3LN-HSA alone or in combination with liposomal-monophosphoryl lipid A (LMPLA)

220 adjuvant had significantly reduced parasite load (91.7-99.9%) in all tissues tested, reduced

221 cardiac inflammation, myocyte necrosis, and T cell infiltration in comparison to control

222 groups. The trypanolytic effect of anti-α-Gal Abs occurred in a complement-independent

223 manner, similar to that in *Leishmania* parasites [5]. These Abs specifically bind to the

224 parasites and destabilize the plasma membrane leading to the surface coat disruption,

225 agglutination, and death. The authors further demonstrated that purified murine IgG Abs to

226 Galα3LN-HSA effectively block the host cell infection and intracellular proliferation of the

227   parasite. Immunization with Galα3LN-HSA + LMLP increased the production of IgG1 and

228   IgG2b subclasses and significantly increased levels of serum cytokines, chemokines, and

229   growth factors, in particular IL-2, IL-4, IL-9, IL-15, C-C chemokine motif ligand 3 (CCL3),

230   and vascular endothelial growth factor (VEGF). Furthermore, a significant increase of

231   antigen-induced CD4$^+$ and CD8$^+$ T cells was observed along with a considerable expansion

232   of memory CD4$^+$CD44$^+$ T cells, but not memory CD8$^+$CD44$^+$ T cells, which are considered

233   to be critical for protective and long-lasting α-Gal immunity against *T. cruzi* infection. Based

234   on the overall results, the authors propose that the production of protective anti-α-Gal Abs to

235   Galα3LN-HSA is mediated through a T cell-dependent B cell memory mechanism.

236

237   **Challenges in developing an α-Gal-based vaccine**

238   *Carrier protein*

239   The evolutionary adaptation in crown catarrhines and their ability to induce a protective α-

240   Gal immune response against infection and multiplication of pathogens suggests the

241   possibility of developing α-Gal-based interventions for control of multiple diseases affecting

242   humans, birds, and fish [4-6,8,10,11,13,14,30]. The prospective vaccine antigen should be

243   capable to induce antigen-specific plasma cells secreting protective Abs and development of

244   memory T and B cells in order to provide efficient and long-lasting protection [2,4,5,8].

245   Nevertheless, the target carbohydrate antigen must not induce autoimmune- or allergy-related

246   anti-α-Gal IgE Abs following immunization [2,4,5,8]. In contrast to protein antigens,

247   carbohydrates are classified as thymus-independent antigens with poor immunogenic

248   reactivity [58]. Due to the lack of T cell activation, B cells predominantly produce IgM and

249   IgG Abs of low affinity and the immune response induced by carbohydrates is often short-

250   lived [59-62]. Therefore, covalent conjugation of carbohydrate antigens to carrier protein has

251   been proposed to overcome the immunoreactive issue [2]. Synthetic α-Gal-containing NGPs

252   coupled to BSA or HSA have been often used for classical immunization by injection with

253   great success in mice [4,5,8,11,30]. It is important, however, to note that the protein linker

254   can sometimes induce the production of anti-linker Abs and influence the immune response

255   against desired glycan antigen [5]. To minimize the cross-reactions and to achieve a strong

256   and more specific immune response towards specific glycotope, smaller and more flexible

257   protein linkers should be used for glycan conjugation [63,64]. It has also been shown that

258   pre-existing natural anti-α-Gal Abs can enhance the immunogenicity of antigens exhibiting α-

259   gal epitopes by increasing a T cell-dependent immune response following immunization [65-

260   68]. In this sense, combining the α-Gal carbohydrates with other protein vaccine candidates

261   could improve the immunogenicity of the α-Gal vaccine formulations [4,69].

262

263   *Structure of the α-Gal epitopes and immunization route*

264   The structural configuration of the epitope and the immunization route are other important

265   considerations for the successful α-Gal vaccine development. Immunization with linear

266   Galα3LN (Galα1-3Galβ1-4GlcNAc trisaccharide), which is structurally nearly identical to

267   native *T. cruzi* surface glycotope, provided the full protection against lethal *T. cruzi* challenge

268   in *ggta1*-KO mice [3,8]. The naturally occurring human anti-α-Gal Abs induced by gut

269   microbiota have a considerably weaker binding activity to the linear Galα3LN on tGPI-

270   mucins of *T. cruzi* and lower trypanolytic effect on metacyclic trypomastigotes than parasite-

271   specific anti-α-Gal Abs [3,45,49]. Indeed, the immunodominant Galα3LN glycan on tGPI-

272   mucins is a major target for the protective anti-α-Gal Abs and it has not been yet reported in

273   any enterobacteria [41], suggesting that gut enrichment with α-Gal-containing bacteria may

274   not be as efficient as immunization with synthetic NGPs for *T. cruzi* infection [8]. On the

275   other hand, the experimental study by Mateos-Hernández et al. [10] showed that oral

276   administration of *E. coli* O86:B7 protects turkeys (*Meleagris gallopavo*) from developing

277 respiratory clinical aspergillosis, while subcutaneous immunization with the synthetic Galα1-

278 3Gal-BSA failed to protect against an infectious challenge with *A. fumigatus*. *Escherichia*

279 *coli* O86:B7-treated turkeys had substantially lower granulomatous lesion score,

280 inflammatory response, and lower hyphae score than immunized birds or those from control

281 groups. Interestingly, the protective effect of *E. coli* O86:B7 was not due to the increased

282 production of serum anti-α-Gal IgY, but it is likely associated with a considerable reduction

283 of anti-α-Gal IgA Abs in the lungs of infected birds. The mechanism by which *E. coli*

284 O86:B7 abrogates anti-α-Gal IgA response in the lungs of immunized turkeys remains to be

285 elucidated, but it may be associated with the production of α-Gal-specific **regulatory T cells**

286 **(Tregs)** in the guts, which can then migrate to the lungs and induce tolerance to the infection.

287 Based on these findings, it can be suggested that the efficacy of immunization with α-Gal and

288 the activation of the specific protective immunity may be dependent on the source, i.e.

289 configuration of the α-Gal epitopes and the route of its administration (immunization through

290 injection *vs* oral administration).

291

292 ***Infection route***

293 Nevertheless, the protective effect of the α-Gal-induced immunity may also be depending on

294 the route of pathogen infection. In a recently published study, zebrafish (*Danio rerio*) was

295 introduced as a new animal model to investigate the possibility of using α-Gal-based vaccine

296 formulation for the control of tuberculosis [11]. In two separate experiments, zebrafish were

297 first immunized by intraperitoneal injection of synthetic Galα1-3Gal-BSA either in

298 combination with ISA 71 VG adjuvant or without it and then challenged with *Mycobacterium*

299 *marinum*, a bacterium causing chronic tuberculosis-like diseases in fish [70-72]. The

300 protection against the mycobacterial infection, characterized by increased production of

301 protective anti-α-Gal IgM Abs, opsonization of *M. marinum,* promotion of FcR-mediated

302 phagocytosis and macrophage activation, was only observed in zebrafish vaccinated with

303 Galα1-3Gal-BSA and infected by mucosal exposure to *M. marinum*, but not in those infected

304 intraperitoneally.

305

306 ***Bacteria used for oral immunization***

307 In most of the studies reported here, *E. coli* O86:B7 strain was proved to successfully elicit

308 protective α-Gal immunity in *ggta1*-KO mouse and bird models [4,10]. No apparent

309 morbidity or mortality occurred in any of the test or control *ggta1*-KO mice due to oral

310 gavage with live *E. coli* O86:B7. Mice remained healthy and active, with no detectable

311 weight loss, diarrhoea, or observable abnormalities [4,73]. Humans orally inoculated with the

312 parental strain of *E. coli* O86:B7, *E. coli* O86, developed increased blood group B Abs [74].

313 However, *E. coli* O86:B7 was associated with a gastroenteritis outbreak [75]. Therefore, gut

314 colonization with probiotic *E. coli* Nissle 1917 (ECN1917) strain offers a much safer and

315 better alternative [47] also because this strain has higher α-Gal content compared to *E. coli*

316 O86:B7 and it is possibly able to induce a stronger α-Gal immune response. Using Gram-

317 positive bacteria as a probiotic-based vaccine would also be an option, but in contrast to

318 Gram-negative enterobacteria, they do not have immunogenic lipopolysaccharide (LPS)

319 components [76], which may have an impact on the immune response against α-Gal in the

320 intestinal mucosa [47]. To overcome the possible low antigenicity, probiotic-based vaccines

321 using Gram-positive bacteria could be combined with TLR4 agonist for LPS [13,47]. This

322 can be implemented by transforming candidate Gram-positive bacteria with a plasmid

323 containing LPS specific peptide mimotopes [77], as previously observed in *Lactobacillus*

324 *casei* [78]. Alternatively, a plasmid containing bacterial *ggta1* reported in *E. coli* and other

325 bacteria could be transferred to any bacteria and theoretically used as a probiotic-based

326 vaccine [47].

327

Concluding remarks

328 **Concluding remarks**

329 Immunization by α-Gal either through injection of synthetic NGPs or oral administration of

330 α-Gal-expressing bacteria represents a promising and innovative strategy for the prevention

331 and control of parasitic diseases in humans and animals. A combination of protective protein

332 antigens with α-Gal-containing compounds may improve vaccine efficacy by activating

333 complementary immune protective mechanisms. Furthermore, these interventions have the

334 potential to induce an efficient and long-lasting protective immune response targeting other

335 pathogenic agents with the surface α-Gal modifications including *Borrelia burgdorferi* sensu

336 lato, *Anaplasma phagocytophilum*, Newcastle disease virus, human immunodeficiency virus

337 (HIV), and measles virus [7,14,23,79]. However, all currently available data are gathered in

338 experimental studies employing the humanized mouse or turkey/chicken and fish models [4-

339 6,8,10,11,30], which opens up the question of whether these promising findings in animals

340 can be reliably translated to humans (see **Outstanding Questions**). Therefore, more clinical

341 studies are still needed to optimize the vaccine antigen and standardize the immunization

342 protocols and to better understand the mechanisms underlying the protective immunity

343 induced by α-Gal. There is still much to be learned (see **Outstanding Questions**), but in the

344 era of the -omics technologies, the development of efficient immunization interventions

345 based on the α-Gal antigens against multiple pathogens appears to be closer to reach than

346 ever.

347

348 **Disclaimer Statement**

349 The authors declare that they have no conflicts of interest.

350

351 **References**

352 1. Astronomo, R.D. and Burton, D.R. (2010) Carbohydrate vaccines: developing sweet

353   solutions to sticky situations? *Nat. Rev. Drug Discov*. 9, 308–324.

354 2. Jaurigue, J.A. and Seeberger, P.H. (2017) Parasite carbohydrate vaccines. *Front. Cell.*

355   *Infect. Microbiol*. 7, 248.

356 3. Almeida, I.C. *et al*. (1994) Lytic anti-alpha-galactosyl antibodies from patients with

357   chronic Chagas' disease recognize novel O-linked oligosaccharides on mucin-like

358   glycosyl-phosphatidylinositol-anchored glycoproteins of *Trypanosoma cruzi. Biochem. J.*

359   304, 793–802.

360 4. Yilmaz, B. *et al*. (2014) Gut microbiota elicits a protective immune response against

361   malaria transmission. *Cell* 159, 1277–1289.

362 5. Iniguez, E. *et al*. (2017) An α-Gal-containing neoglycoprotein-based vaccine partially

363   protects against murine cutaneous leishmaniasis caused by *Leishmania major*. PLoS

364   Negl. Trop. Dis. 11, e0006039.

365 6. Moura, A.P.V. *et al*. (2017) Virus-like particle display of the α-Gal carbohydrate for

366   vaccination against *Leishmania* infection. *ACS Cent. Sci*. 3, 1026–1031.

367 7. Hodžić, A. *et al*. (2019); Tick bites induce anti-α-Gal antibodies in dogs. *Vaccines (Basel)*

368   7(3).

369 8. Portillo, S. *et al*. (2019) A prophylactic α-Gal-based glycovaccine effectively protects

370   against murine acute Chagas disease. *NPJ Vaccines* 4, 13.

371 9. Hodžić, A. *et al*. (2020) Infection with *Toxocara canis* Inhibits the Production of IgE

372   Antibodies to α-Gal in Humans: Towards a Conceptual Framework of the Hygiene

373   Hypothesis?. *Vaccines (Basel)*. 8, 167.

374 10. Mateos-Hernández, L. *et al*. (2020) Gut microbiota abrogates anti-α-Gal IgA response in

375   lungs and protects against experimental *Aspergillus* infection in poultry. *Vaccines (Basel)*

376   8, 285.

377   11. Pacheco, I. *et al*. (2020) Vaccination with alpha-Gal protects against mycobacterial

378   infection in the zebrafish model of tuberculosis. *Vaccines (Basel)* 8, 195.

379   12. Rodrigues, J.A. *et al*. (2015) Parasite glycobiology: A bittersweet symphony. *PLoS*

380   *Pathog*. 11, e1005169.

381   13. Cabezas-Cruz, A. *et al*. (2016) Control of vector-borne infectious diseases by human

382   immunity against α-Gal. *Expert Rev. Vaccines* 15, 953–955.

383   14. Cabezas-Cruz, A. and de la Fuente, J. (2017) Immunity to α-Gal: Toward a single-antigen

384   pan-vaccine to control major infectious diseases. *ACS Cent. Sci*. 3, 1140–1142.

385   15. van Nunen, S.A. *et al*. (2007) An association between *Ixodes holocyclus* tick bite

386   reactions and red meat allergy. *Intern. Med. J*. 37 (Suppl. 5), A132.

387   16. Chung, C.H. *et al*. (2008) Cetuximab-induced anaphylaxis and IgE specific for galactose-

388   alpha-1,3-galactose. *N. Engl. J. Med*. 358, 1109–1117.

389   17. Commins, S.P. *et al*. (2009) Delayed anaphylaxis, angioedema, or urticaria after

390   consumption of red meat in patients with IgE antibodies specific for galactose-α-1,3-

391   galactose. *J. Allergy Clin. Immunol*. 123, 426–433.

392   18. Commins, S.P. *et al*. (2011) The relevance of tick bites to the production of IgE

393   antibodies to the mammalian oligosaccharide galactose-α-1,3-galactose. *J. Allergy Clin.*

394   *Immunol*. 127, 1286–1293.e6.

395   19. Platts-Mills, T.A. *et al*. (2015) Anaphylaxis to the carbohydrate side chain alpha-gal.

396   *Immunol. Allergy. Clin. North. Am*. 35, 247–260.

397   20. Hodžić, A. *et al*. (2019) Delayed hypersensitivity reaction to mammalian galactose-α-1,3-

398   galactose (α-Gal) after repeated tick bites in a patient from France. *Ticks Tick. Borne Dis*.

399   10, 1057–1059.

400   21. Fischer, J. *et al.* (2016) Clinical spectrum of α-Gal syndrome: from immediate-type to

401   delayed immediate-type reactions to mammalian innards and meat. *Allergo. J. Int.* 25,

402   55–62.

403   22. Wilson, J.M. *et al.* (2017) Galactose-α-1,3-Galactose: Atypical food allergen or model

404   IgE hypersensitivity? *Curr. Allergy Asthma Rep.* 17, 8.

405   23. Cabezas-Cruz, A. *et al.* (2019) Environmental and molecular drivers of the α-Gal

406   syndrome. *Front. Immunol.* 10, 1210.

407   24. Mateos-Hernández, L. *et al.* (2017) Tick-host conflict: Immunoglobulin E antibodies to

408   tick proteins in patients with anaphylaxis to tick bite. *Oncotarget* 8, 20630–20644.

409   25. Cabezas-Cruz, A. *et al.* (2018) Tick galactosyltransferases are involved in α-Gal synthesis

410   and play a role during *Anaplasma phagocytophilum* infection and Ixodes scapularis tick

411   vector development. *Sci. Rep.* 8, 14224.

412   26. Crispell, G. *et al.* (2019) Discovery of α -Gal-containing antigens in North American tick

413   species believed to induce red meat allergy. *Front. Immunol.* 10, 1056.

414   27. Park, Y. *et al.* (2020) α-Gal and cross-reactive carbohydrate determinants in the N-

415   glycans of salivary glands in the Lone Star Tick, *Amblyomma americanum. Vaccines* 8,

416   18.

417   28. Fischer, J. *et al.* (2020) Spatial distribution of alpha-gal in Ixodes ricinus – A histological

418   study. *Ticks Tick Borne Dis.* 11, 101506.

419   29. Cabezas-Cruz, A. *et al.* (2017) Salivary prostaglandin E2: Role in tick-induced allergy to

420   red meat. *Trends Parasitol.* 33:495–498.

421   30. Yan, L.M. *et al.* (2020) Heterosubtypic protection induced by a live attenuated influenza

422   virus vaccine expressing galactose-α-1,3-galactose epitopes in infected cells. *mBio.* 11,

423   e00027.

424   31. Galili, U. *et al*. (1988) Man, apes, and Old World monkeys differ from other mammals in
425   the expression of alpha-galactosyl epitopes on nucleated cells. *J. Biol. Chem*. 263, 17755–
426   17762.

427   32. Blanken, W.M. and Van den Eijnden, D.H. (1985) Biosynthesis of terminal Galα1-
428   3Galβ1-4GlcNAc-R oligosaccharide sequences on glycoconjugates. Purification and
429   acceptor specificity of a UDP-Gal:N-acetyllactosaminide α1-3-galactosyltransferase from
430   calf thymus. *J. Biol. Chem*. 260, 12927–12934.

431   33. Larsen, L.D. *et al*. (1990) Frameshift and nonsense mutations in a human genomic
432   sequence homologous to a murine UDP-Gal:β-D-Gal(1,4)-D-GlcNAcα(1,3)-
433   galactosyltransferase cDNA. *J. Biol. Chem*. 265, 7055–7061.

434   34. Galili, U. and Swanson, K. (1991) Gene sequences suggest inactivation of α-1,3-
435   galactosyltransferase in catarrhines after the divergence of apes from monkeys. *Proc.*
436   *Natl. Acad. Sci. USA* 88, 7401–7404.

437   35. Galili, U. (1993) Evolution and pathophysiology of the human natural anti-α-galactosyl
438   IgG (anti-Gal) antibody. *Springer Semin. Immunopathol*. 15, 155–171.

439   36. McKenzie, I.F *et al*. (1999) Definition and characterization of chicken Gal α(1,3)Gal
440   antibodies. *Transplantation* 67, 864–870.

441   37. Macher, B.A. and Galili, U. (2008) The Galα1,3Galβ1,4GlcNAc-R (α-Gal) epitope: A
442   carbohydrate of unique evolution and clinical relevance. *Biochim. Biophys. Acta*. 1780,
443   75–88.

444   38. Galili, U. *et al*. (1984) A unique natural human IgG antibody with anti-α-galactosyl
445   specificity. *J. Exp. Med*. 160, 1519–1531.

446   39. Galili, U. *et al*. (1987) Evolutionary relationship between the natural anti-Gal antibody
447   and the Galα1-3Gal epitope in primates. *Proc. Natl. Acad. Sci. USA* 84, 1369–1373.

448   40. Rispens, T. *et al*. (2013) IgE Production to α-Gal is accompanied by elevated levels of

449   specific IgG1 antibodies and low amounts of IgE to blood group B. *PLoS One* 8, e55566.

450   41. Wilkinson, S.G. (1996) Bacterial lipopolysaccharides - themes and variations. *Prog. Lipid*

451   *Res*. 35, 283–343.

452   42. Galili, U. (2013) Anti-Gal: an abundant human natural antibody of multiple pathogeneses

453   and clinical benefits. *Immunology* 140, 1–11.

454   43. Montassier, E. *et al*. (2019) Distribution of bacterial α1,3-galactosyltransferase genes in

455   the human gut microbiome. *Front. Immunol*. 10, 3000.

456   44. Pérez-Cruz, M. *et al*. (2017) Cytokine profile associated with selective removal of natural

457   anti-α-Gal antibodies in a sepsis model in Gal-KO mice. *Biochemistry (Mosc)* 82, 205–

458   212.

459   45. Almeida, I.C. *et al*. (1991) Complement-mediated lysis of *Trypanosoma cruzi*

460   trypomastigotes by human anti-alpha-galactosyl antibodies. *J. Immunol*. 146, 2394–2400.

461   46. Al-Salem, W.S. et al. (2014) Detection of high levels of anti-alpha-galactosyl antibodies

462   in sera of patients with Old World cutaneous leishmaniasis: a possible tool for diagnosis

463   and biomarker for cure in an elimination setting. *Parasitology* 141, 1898–1903.

464   47. Cabezas-Cruz, A. and de la Fuente, J. (2017) Immunity to α-Gal: The opportunity for

465   malaria and tuberculosis control. *Front. Immunol*. 8, 1733.

466   48. Cabezas-Cruz, A. *et al*. (2017) Effect of blood type on anti-α-Gal immunity and the

467   incidence of infectious diseases. *Exp. Mol. Med*. 49, e301.

468   49. Schocker,   N.S.   *et   al*.   (2016)   Synthesis   of   Galα(1,3)Galβ(1,4)GlcNAcα-,

469   Galβ(1,4)GlcNAcα- and GlcNAc-containing neoglycoproteins and their immunological

470   evaluation in the context of Chagas disease. *Glycobiology* 26, 39–50.

471   50. Galili, U. (2005) The α-gal epitope and the anti-Gal antibody in xenotransplantation and

472   in cancer immunotherapy. *Immunol. Cell Biol*. 83, 674–686.

473 51. Ramasamy, R. and Reese, R.T. (1986) Terminal galactose residues and the antigenicity of

474 *Plasmodium falciparum* glycoproteins. *Mol. Biochem. Parasitol*. 19, 91–101.

475 52. Jakobsen, P.H. *et al*. (1987) Soluble *Plasmodium falciparum* antigens contain

476 carbohydrate moieties important for immune reactivity. *J. Clin. Microbiol*. 25, 2075–

477 2079.

478 53. Ravindran, B. *et al*. (1988) Naturally-occurring anti-α-galactosyl antibodies in human

479 *Plasmodium falciparum* infections – a possible role for autoantibodies in malaria.

480 *Immunol. Lett*. 19, 137–141.

481 54. Ramasamy, R. and Field, M.C. (2012) Terminal galactosylation of glycoconjugates in

482 *Plasmodium falciparum* asexual blood stages and *Trypanosoma brucei* bloodstream

483 trypomastigotes. *Exp. Parasitol*. 130, 314–320.

484 55. Lopera-Mesa, T.M. *et al*. (2015) Effect of red blood cell variants on childhood malaria in

485 Mali: A prospective cohort study. *Lancet Haematol*. 2, e140-9.

486 56. Avila, J.L. *et al*. (1989) Immunogenic Galα1-3Gal carbohydrate epitopes are present on

487 pathogenic American *Trypanosoma* and *Leishmania*. J. Immunol. 142, 2828–2834.

488 57. Schneider, P. *et al*. (1993) Characterization of glycoinositol phospholipids in the

489 amastigote stage of the protozoan parasite *Leishmania major*. *Biochem. J*. 295 (Pt 2),

490 555–564.

491 58. Weintraub, A. (2003) Immunology of bacterial polysaccharide antigens. *Carbohydr. Res*.

492 338, 2539–2547.

493 59. Mond J.J. *et al*. (1995) T-cell-independent antigens type-2. *Annu. Rev. Immunol*. 13, 655–

494 692.

495 60. Adams, E.W. *et al*. (2008) Carbohydrate-mediated targeting of antigen to dendritic cells

496 leads to enhanced presentation of antigen to T cells. *Chembiochem*. 9, 294–303.

497   61. Berti, F. and Adamo, R. (2013) Recent mechanistic insights on glycoconjugate vaccines

498   and future perspectives. *ACS Chem. Biol*. 8, 1653–1663.

499   62. Hütter, J. and Lepenies, B. (2015) Carbohydrate-based vaccines: an overview. *Methods*

500   *Mol. Biol*. 1331, 1–10.

501   63. Buskas, T. *et al*. (2004) The immunogenicity of the tumor-associated antigen Lewis(y)

502   may be suppressed by a bifunctional cross-linker required for coupling to a carrier

503   protein. *Chemistry* 10, 3517–3524.

504   64. Gotze, S. *et al*. (2015) Investigation of the protective properties of

505   glycosylphosphatidylinositol-based vaccine candidates in a *Toxoplasma gondii* mouse

506   challenge model. *Glycobiology* 25, 984–991.

507   65. Galili, U. *et al*. (1996) Enhancement of antigen presentation of influenza virus

508   hemagglutinin by the natural human anti-Gal antibody. *Vaccine* 14, 321–328.

509   66. Abdel-Motal, U. *et al*. (2006) Increased immunogenicity of human immunodeficiency

510   virus gp120 engineered to express Galα1-3Galα1-4GlcNAc-R epitopes. *J. Virol*. 80,

511   6943–6951.

512   67. Abdel-Motal, U.M. *et al*. (2007) Immunogenicity of influenza virus vaccine is increased

513   by anti-gal-mediated targeting to antigen-presenting cells. J. Virol. 81, 9131–9141.

514   68. Abdel-Motal, U.M. *et al*. (2009) Mechanism for increased immunogenicity of vaccines

515   that form in vivo immune complexes with the natural anti-Gal antibody. *Vaccine* 27,

516   3072–3082.

517   69. Benatuil, L. *et al*. (2005) The influence of natural antibody specificity on antigen

518   immunogenicity. *Eur. J. Immun*. 35, 2638–2647.

519   70. Cronan, M.R. and Tobin, D.M. (2014) Fit for consumption: Zebrafish as a model for

520   tuberculosis. *Dis. Mod. Mec*. 7, 777–784.

521 71. López, V. *et al*. (2018) Heat-inactivated *Mycobacterium bovis* protects zebrafish against

522 mycobacteriosis. *J. Fish Dis*. 41, 1515–1528.

523 72. Risalde, M.A. *et al*. (2018) Control of mycobacteriosis in zebrafish (*Danio rerio*)

524 mucosally vaccinated with heat-inactivated *Mycobacterium bovis*. *Vaccine* 36, 4447–

525 4453.

526 73. Posekany, K.J. *et al*. (2002) Induction of cytolytic anti-Gal antibodies in α-1,3-

527 galactosyltransferase gene knockout mice by oral inoculation with *Escherichia coli*

528 O86:B7 bacteria. *Infect. Immun*. 70, 6215–6222.

529 74. Springer, G.F, Horton, R.E. (1969) Blood group isoantibody stimulation in man by

530 feeding blood group-active bacteria. *J Clin Invest.* 48, 1280-1291.

531 75. Pal, S.C. *et al*. (1969) An extensive community outbreak of enteropathogenic *Escherichia*

532 *coli* O86: B7 gastroenteritis. Bull. *World Health Organ*. 41, 851–858.

533 76. Galili, U. *et al*. (1988) Interaction between human natural anti-alpha-galactosyl

534 immunoglobulin G and bacteria of the human flora. *Infect. Immun*. 56, 1730–1737.

535 77. Shanmugam, A. *et al*. (2012) Synthetic toll like receptor-4 (TLR-4) agonist peptides as a

536 novel class of adjuvants. *PLoS One* 7:e30839.

537 78. Mangold, A. et al. (2012) Anti-alpha-Gal antibody titres remain unaffected by the

538 consumption of fermented milk containing *Lactobacillus casei* in healthy adults. *Int. J.*

539 *Food Sci. Nutr*. 63, 278–282.

540 79. Galili, U. (2019) Evolution in primates by "Catastrophic-selection" interplay between

541 enveloped virus epidemics, mutated genes of enzymes synthesizing carbohydrate

542 antigens, and natural anti-carbohydrate antibodies. *Am. J. Phys. Anthropol*. 168, 352–363.

543

544 **Glossary**

545 **Antigen-presenting cells (APCs):** are a large group of various cells (i.e., macrophages, dendritic cells, B lymphocytes) that induce the cellular immune response by processing and exposing an antigen to T cells

548 **Chagas disease:** a severe tropical disease caused by the parasite *Trypanosoma cruzi*, which is transmitted to humans and animals mostly by triatomine bugs. It is also referred to as American trypanosomiasis.

551 **Complement system**: an integral part of the innate immune system that supports antibodies and phagocytes to clear foreign particles, microbes, and damaged body cells from an organism. The system also promotes inflammation and opsonization.

554 **Cytokines:** a large group of small signalling proteins, peptides, or glycoproteins that are secreted by cells of the immune system. They are involved in the interactions and communications between cells, and the stimulation of the cell movement toward infection sites. Cytokines include interferons (IF), interleukins (IL), chemokines, and tumour necrosis factors (TNF).

559 **Glycotope:** a specific part of a carbohydrate antigen that is recognized by the immune system, in particular antibodies, B cells, or T cells.

561 **Leishmaniasis:** a vector-borne disease of medical and veterinary concern caused by the protozoan parasites from the genus *Leishmania*. The parasites are transmitted through the bites of infected phlebotomine sandflies. Over 20 *Leishmania* species infect humans worldwide and the diseases can be displayed as cutaneous, visceral, and mucocutaneous forms.

566 **Nuclear factor kappa-light-chain-enhancer (NF-κB):** a protein complex found in almost all animal cell types, which controls transcription of DNA, cytokine production, and cell survival. NF-κB is involved in rapid cellular responses to various stimuli and plays a key role in triggering the protective immune response to infections.

570 **Opsonization:** a process by which a microbial agent or a cell is marked for ingestion and
571 destruction by phagocytes.

572 **Regulatory T cells (Tregs):** subpopulation of T cells, which have a role in modulating other
573 cells of the immune system. Tregs control the immune response to self-antigens and prevent
574 autoimmune diseases. In general, they suppress or downregulate the induction and
575 proliferation of effector T cells.

576 **Sterile immunity:** a unique immune status, which prevents effective pathogen infection into
577 the host and is different from the immunity that allows infection but with subsequent
578 successful eradication of the pathogen.

579 **Toll-like receptors (TLRs):** a class of proteins that play a crucial role in the innate immune
580 system. They are usually expressed on macrophages and dendritic cells that pathogen-
581 associated molecular patterns derived from various infectious agents.

582

583 **Figure caption**

584 **Figure 1, Key Figure. α-Gal vaccination induces protection against several pathogens.**
585 Parental and/or oral immunization with preparations containing the carbohydrate α-Gal has
586 been shown to protect against kinetoplastid (*Trypanosoma cruzi* and *Leishmania* spp.),
587 apicomplexan (*Plasmodium* spp.), mycobacterial (*Mycobacterium marinum*), and fungal
588 (*Aspergillus fumigatus*) pathogens in different animal models.

Table 1. An overview of α-Gal antigens used as vaccine candidates against parasites and other infectious agents and mechanisms of protective α-Gal immunity.

Targeted pathogen	Source of α-Gal epitope	Animal model	Immunization route	Infection route	Mechanism of protective immunity	Reference
Plasmodium berghei, *P. yoelii*	*Escherichia coli* O86:B7, rRBCM, α-Gal-BSA	C57BL/6 α1,3GT-knockout mouse	PO, IP	ID, IV	Lytic activity of anti-α-Gal IgM and IgG antibodies (complement activation)	[4]
Leishmania major, L. infantum, *L. amazonensis*	Galα(1,6)Galβ-BSA, Qβ-α-Gal	C57BL/6 α1,3GT-knockout mouse	SC	FPI, IP	Lytic activity of anti-α-Gal IgG antibodies (complement independent), upregulation of Th1 cytokines, upregulation of memory CD4$^+$CD44$^+$, CD8$^+$CD44$^+$ and CD4$^+$CD69$^+$ T cells	[5,6]
Trypanosoma cruzi	Galα1-3Galβ1-4GlcNAc-HSA	C57BL/6 α1,3GT-knockout mouse	IP	IP	Trypanolytic activity of anti-α-Gal IgG antibodies (complement independent), upregulation of cytokines, chemokines and growth factors, expansion of antigen-specific memory CD4$^+$CD44$^+$ T cells	[8]
Mycobacterium marinum	Galα1-3Gal-BSA	Zebrafish (*Danio rerio*)	IP, ME	IP	B cell maturation, antibody-mediated opsonisation, FcR-mediated phagocytosis, macrophage response, interference with the α-Gal antagonistic effect of the TLR2/NF-kB-mediated immune response, upregulation of proinflammatory cytokines	[11]

| *Aspergillus fumigatus* | *Escherichia coli* O86:B7, Galα1-3Gal-BSA | Turkey (*Meleagris gallopavo*) | PO, SC | IT | Decreased anti-α-Gal IgA levels in the lungs, production of α-Gal-specific Tregs (putative mechanism) | [10] |

Abbreviations: FPI – footpad injection; ID – intradermally; IP – intraperitoneally; IT – intratracheally; IV – intravenously; ME – mucosal exposure (i.e., immersion in water containing *M. marinum*); PO – perorally; SC – subcutaneously.